NCT04263935 Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
| NCT ID | NCT04263935 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henan Cancer Hospital |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2019-01-03 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2019-01-03 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed as lymphoma (according to WHO 2017 classification criteria) 2. Life expectancy no less than 3 months 3. Agreeing to sign the written informed consents Exclusion Criteria: 1. Other malignant tumor history or active malignant tumor need be treated 2. Researchers determine unsuited to participate in this trial
Contact & Investigator
Yanyan Liu, M.D. Ph.D
STUDY DIRECTOR
Henan Cancer Hospital
Frequently Asked Questions
Who can join the NCT04263935 clinical trial?
This trial is open to participants of all sexes, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04263935 currently recruiting?
Yes, NCT04263935 is actively recruiting participants. Contact the research team at yyliu@zzu.edu.cn for enrollment information.
Where is the NCT04263935 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT04263935 clinical trial?
NCT04263935 is sponsored by Henan Cancer Hospital. The principal investigator is Yanyan Liu, M.D. Ph.D at Henan Cancer Hospital. The trial plans to enroll 200 participants.